3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
8
Small Cell Lung Carcinoma
6
Fallopian Tube Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Central Nervous System Neoplasms
2
Uterine Cervical Neoplasms
1
SCLC
1
Rhabdoid Tumor
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Choroid Plexus Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
Cyclophosphamide
10
fludarabine
7
pomalidomide
5
pembrolizumab
5
Dexamethasone
5
daratumumab
4
obinutuzumab
3
glofitamab
3
fludarabine phosphate
3
abemaciclib
3
Rituximab
3
Melphalan
3
Immunotherapy, Adoptive
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
pirtobrutinib
2
palbociclib
2
cemiplimab
2
blinatumomab
2
Temozolomide
2
Sirolimus
2
Oxaliplatin
2
Nivolumab
2
Mesna
2
Letrozole
2
Injections
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Topotecan
×
30 days
×
Clear all
No trials found.